Is it the Right Time to Add CRL Stock to Your Portfolio Now?

Key Takeaways Charles River's DSA segment drives growth with rising outsourcing demand across pharma and biotech.Recent acquisitions and collaborations expand CRL's drug discovery, safety testing and AI capabilities.Forex pressures and cautious biotech spending create headwinds for Charles River's revenue growth.Charles River Laboratories International, Inc. (CRL) is well-poised to grow in the coming quarters, courtesy of the favorable growth prospects in its Discovery and Safety Assessment (“DSA”) segment. ...